ALNYLAM PHARMACEUTICALS INC

NASDAQ: ALNY (Alnylam Pharmaceuticals, Inc.)

Kemas kini terakhir: 12 Jan, 10:30AM

361.28

-37.01 (-9.29%)

  • 1H -9.29%
  • 5H 0.56%
  • 1B -9.81%
  • 6B 9.88%
  • Tahun Ke Tarikh -9.72%
  • 1T 30.55%
  • 5T 105.63%
Penutupan Terdahulu 398.29
Buka 399.40
Jumlah Dagangan 1,523,115
Purata Dagangan (3B) 1,293,967
Modal Pasaran 47,730,077,696
Harga / Pendapatan (P/E TTM) 1,129.00
Harga / Pendapatan (P/E Ke hadapan) 49.02
Harga / Jualan (P/S) 14.82
Harga / Buku (P/B) 202.20
Julat 52 Minggu
205.87 (-43%) — 495.55 (37%)
Tarikh Pendapatan 30 Oct 2025
Margin Keuntungan -11.49%
Margin Operasi (TTM) 3.04%
EPS Cair (TTM) -2.11
Pertumbuhan Hasil Suku Tahunan (YOY) 20.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 2,358.25%
Nisbah Semasa (MRQ) 3.04
Aliran Tunai Operasi (OCF TTM) -45.11 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 223.09 M
Pulangan Atas Aset (ROA TTM) -1.79%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Alnylam Pharmaceuticals, Inc. Menaik Menaik

AISkor Stockmoo

1.2
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam 2.0
Volatiliti Harga 2.0
Purata Bergerak Teknikal 1.0
Osilator Teknikal -0.5
Purata 1.20

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALNY 48 B - 1,129.00 202.20
REGN 80 B 0.47% 18.05 2.54
BMRN 11 B - 21.48 1.73
RPRX 24 B 2.18% 23.09 2.63
CRSP 5 B - - 2.76
BBIO 15 B - - -

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Core
% Dimiliki oleh Orang Dalam 3.81%
% Dimiliki oleh Institusi 97.56%
Julat 52 Minggu
205.87 (-43%) — 495.55 (37%)
Julat Harga Sasaran
351.00 (-2%) — 549.00 (51%)
Tinggi 549.00 (Jefferies, 51.96%) Beli
Median 517.50 (43.24%)
Rendah 351.00 (Leerink Partners, -2.85%) Pegang
Purata 485.30 (34.33%)
Jumlah 8 Beli, 2 Pegang
Harga Purata @ Panggilan 401.81
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
RBC Capital 20 Jan 2026 465.00 (28.71%) Beli 355.53
Wells Fargo 20 Jan 2026 376.00 (4.07%) Pegang 355.53
11 Nov 2025 479.00 (32.58%) Pegang 451.95
B of A Securities 12 Jan 2026 529.00 (46.42%) Beli 370.91
Needham 12 Jan 2026 529.00 (46.42%) Beli 370.91
Truist Securities 08 Jan 2026 530.00 (46.70%) Beli 399.40
Leerink Partners 15 Dec 2025 351.00 (-2.85%) Pegang 391.50
Stifel 11 Dec 2025 508.00 (40.61%) Beli 412.63
Barclays 31 Oct 2025 527.00 (45.87%) Beli 456.04
Piper Sandler 31 Oct 2025 489.00 (35.35%) Beli 456.04
Jefferies 30 Oct 2025 549.00 (51.96%) Beli 449.56
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
FITZGERALD KEVIN JOSEPH 398.29 370.44 0 106,220
GARG PUSHKAL 398.29 370.91 2,290 953,428
GREENSTREET YVONNE 398.29 370.91 9,426 4,016,500
POULTON JEFFREY V. 398.29 370.91 3,413 1,435,480
TANGULER TOLGA 398.29 370.91 2,290 953,428
Jumlah Keseluruhan Kuantiti Bersih 17,419
Jumlah Keseluruhan Nilai Bersih ($) 7,465,055
Purata Pembelian Keseluruhan ($) 398.29
Purata Jualan Keseluruhan ($) 370.75
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
FITZGERALD KEVIN JOSEPH Pegawai 13 Jan 2026 Jual automatik (-) 2,290 369.96 847,208
FITZGERALD KEVIN JOSEPH Pegawai 12 Jan 2026 Jual (-) 1,510 370.91 560,074
TANGULER TOLGA Pegawai 12 Jan 2026 Jual (-) 1,510 370.91 560,074
POULTON JEFFREY V. Pegawai 12 Jan 2026 Jual (-) 2,780 370.91 1,031,130
GREENSTREET YVONNE Pegawai 12 Jan 2026 Jual (-) 9,577 370.91 3,552,205
GARG PUSHKAL Pegawai 12 Jan 2026 Jual (-) 1,510 370.91 560,074
FITZGERALD KEVIN JOSEPH Pegawai 11 Jan 2026 Diperolehi (+) 3,800 398.29 1,513,502
TANGULER TOLGA Pegawai 11 Jan 2026 Diperolehi (+) 3,800 398.29 1,513,502
POULTON JEFFREY V. Pegawai 11 Jan 2026 Diperolehi (+) 6,193 398.29 2,466,610
GREENSTREET YVONNE Pegawai 11 Jan 2026 Diperolehi (+) 19,003 398.29 7,568,705
GARG PUSHKAL Pegawai 11 Jan 2026 Diperolehi (+) 3,800 398.29 1,513,502
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda